MOTS-c: The Mitochondria-Encoded Peptide That Functions as a Circulating Hormone

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA that enters general circulation and influences metabolism, insulin sensitivity, and exercise capacity—though most of the evidence so far comes from animal studies.

What Mitochondria Actually Do

The textbook version of mitochondria has been stable for decades: they are the cell's power plant, converting nutrients into ATP. That description is correct as far as it goes, but it turns out to be incomplete in a way the field wasn't actively looking for until recently. Mitochondria don't just generate energy locally—at least some of them synthesize their own peptides, release those peptides into the bloodstream, and signal to tissues elsewhere. That's endocrine behavior, and it changes how mitochondria fit into metabolic biology more broadly.

MOTS-c is the best-characterized example of this class. It belongs to a group now called mitochondrial-derived peptides (MDPs), and it remains the most studied member of that category.

Where MOTS-c Comes From

What makes MOTS-c structurally unusual is its origin. It is encoded directly within mitochondrial DNA—specifically transcribed from the 12S ribosomal RNA region of the mitochondrial genome—rather than from the nuclear DNA that encodes nearly every other peptide the human body produces. Once translated, it is secreted into circulation, where it acts on tissues well beyond the cell that made it. That combination of mitochondrial origin and systemic reach is what prompted researchers to reclassify it as a circulating hormone rather than a locally acting signal.

The Foundational Research

The Lee and Cohen labs at USC published the foundational work in 2015. In their studies, mice given exogenous MOTS-c showed improved glucose tolerance, reduced fat mass, and greater exercise capacity under models of metabolic and mitochondrial stress. The primary mechanism identified was activation of AMPK—the same energy-sensing switch engaged by metformin and by exercise itself. That mechanistic overlap is why MOTS-c gets described in parts of the literature as an exercise mimetic, though it is worth being precise: "overlapping downstream effects" is not the same as "equivalent to exercise," and that framing has not been validated in controlled human trials.

Both source articles agree on the 2015 origin point and the AMPK mechanism. Neither source includes specific effect sizes from those animal studies, so none are reported here.

What Happens to MOTS-c Levels With Age

Circulating MOTS-c levels decline with age. This is one of the more consistently noted observations in the MDP literature, and it is also one of the genuinely unresolved questions: whether that decline is a meaningful contributor to age-related insulin resistance and metabolic deterioration, or whether it is simply a correlate of aging processes driven by other causes, has not been established. These are meaningfully different claims, and current research has not resolved which is closer to the truth. Treating the correlation as causal would be getting ahead of the evidence.

State of the Human Evidence

Human research on MOTS-c is early. Pharmacokinetic data in humans—how the peptide is absorbed, distributed, metabolized, and cleared—remains limited. Dosing is genuinely unresolved. MOTS-c is not a marketed therapeutic, and neither source article cites completed human clinical trials. The broader category of mitochondrial-derived peptides is currently an active area in longevity and metabolic research, which reflects real scientific interest rather than settled clinical application. The distinction matters: interesting biology and a therapy ready for use are different things, and MOTS-c is firmly in the former category.

One regulatory wrinkle worth noting: because MOTS-c is encoded by mitochondrial rather than nuclear DNA, it raises open questions about how it is classified and regulated—questions that don't apply to most peptides in the same way.

What MyKine Users Might Watch For

Mitochondrial function underlies a meaningful share of what shows up in standard metabolic bloodwork—fasting glucose, insulin sensitivity markers, energy levels, and exercise capacity all reflect, in part, how well this system is working. If several of those markers are trending unfavorably together as you age, that's a reasonable prompt to think about mitochondrial health as a category rather than addressing each marker as an isolated issue.

At this stage, there is no validated protocol for exogenous MOTS-c use in humans, and the field is not there yet in terms of knowing what dose, timing, or form would be appropriate. What is trackable now: fasting glucose, HOMA-IR or fasting insulin, body composition trends, and exercise capacity over time—the same outcomes the animal research used as endpoints. Watching those together, especially in the context of aging, keeps you aligned with where the research is actually focused.

Practical Takeaway

MOTS-c is a mitochondria-encoded peptide that acts as a circulating hormone—a role for mitochondria that was largely uncharacterized before 2015.
Animal studies show effects on glucose tolerance, fat metabolism, and exercise capacity via AMPK activation; human pharmacokinetic and efficacy data remain limited.
Circulating MOTS-c declines with age, but whether that decline is causal in metabolic aging or a correlate is not yet established.
It is not an approved or validated therapeutic; dosing in humans is unresolved and regulatory questions specific to mitochondrially encoded peptides remain open.
MyKine users can track the relevant downstream markers—fasting glucose, insulin, body composition, exercise capacity—as a practical proxy for the systems MOTS-c research is investigating.
Follow the human trial literature rather than animal data alone before drawing conclusions about personal relevance.

Sources

Your Mitochondria Aren't Just Power Plants. They Make Hormones Too — MyKine
Mitochondria Were Never Just Power Plants — 2015 Changed That Story — MyKine